Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category 503A vs 503B Compounding Pharmacies: Key Differences Artixio BPC 157 TB 500 (T4) Blend Pure Health Peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York